Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

New England Journal of Medicine - Tập 373 Số 22 - Trang 2117-2128 - 2015
Bernard Zinman1,2, Christoph Wanner3, John M. Lachin4, David Fitchett5, Erich Bluhmki6, Stefan Hantel6, Michaela Mattheus7, Frans Van de Werf8, Odd Erik Johansen9, Hans J. Woerle7, Uli C. Broedl7, Silvio E. Inzucchi10
1Divisions of Endocrinology, University of Toronto
2Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto
3Department of Medicine, Division of Nephrology, Würzburg University Clinic, Würzburg
4Biostatistics Center, George Washington University, Rockville, MD
5Cardiology, University of Toronto
6Boehringer Ingelheim Pharma, Biberach
7Boehringer Ingelheim Pharma, Ingelheim
8Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT
9Boehringer Ingelheim Norway, Asker, Norway
10Section of Endocrinology, Yale University School of Medicine, New Haven, CT

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(10)60484-9

10.1001/jama.287.19.2570

10.1001/jama.2015.7008

10.1056/NEJMoa1501352

10.1056/NEJMoa1305889

10.1056/NEJMoa1307684

10.1056/NEJMoa0806470

10.1016/S2213-8587(15)00044-3

10.1177/1479164114561992

10.1111/j.1463-1326.2011.01517.x

10.2337/dc12-2673

10.2337/dc13-2105

10.1111/dom.12188

10.1016/S2213-8587(13)70084-6

10.2337/dc13-3055

Rosenstock J, 2015, Diabetes Obes Metab

10.2337/dc14-1096

10.1016/S2213-8587(13)70208-0

Chilton RC, 2014, Diabetes Obes Metab

10.1016/S2213-8587(14)70120-2

10.1186/1475-2840-13-102

Beyersmann J, Allignol A, Schumacher M. Competing risks and multistate models with R. New York: Springer, 2011.

10.1177/1479164114559852

10.1186/1475-2840-13-28

10.2337/dc13-0506

10.1093/eurheartj/ehp507

10.1161/CIRCULATIONAHA.113.005081

10.2337/dc13-1870

Thông tin
Thông tin xuất bản

New England Journal of Medicine

Tập 373 Số 22

2117-2128

Thông tin tác giả